Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection

Bezlotoxumab is marketed for the prevention of recurrent Clostridioides difficile infection (rCDI). Its high cost could be determining its prescription to a different population than that represented in clinical trials. The objective of the study was to verify the effectiveness and safety of bezloto...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Med
Autors principals: Escudero-Sánchez, Rosa, Ruiz-Ruigómez, María, Fernández-Fradejas, Jorge, García Fernández, Sergio, Olmedo Samperio, María, Cano Yuste, Angela, Valencia Alijo, Angela, Díaz-Pollán, Beatriz, Rodríguez Hernández, María Jesús, Merino De Lucas, Esperanza, Martín Segarra, Oriol, Sáez Bejar, Carmen, Armiñanzas Castillo, Carlos, Gutiérrez-Gutiérrez, Belén, Rodríguez-Pardo, Dolors, Ramos-Martínez, Antonio, Torre-Cisneros, Julián, López-Medrano, Francisco, Cobo Reinoso, Javier
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7792623/
https://ncbi.nlm.nih.gov/pubmed/33374989
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm10010002
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars